• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Long duration response in Parkinson's disease: levodopa revisited.

作者信息

Poewe Werner, Espay Alberto J

机构信息

Department of Neurology, Medical University Innsbruck, Innsbruck, Austria.

James J and Joan A Gardner Center for Parkinson's Disease and Movement Disorders, University of Cincinnati, Cincinnati, Ohio, USA.

出版信息

Brain. 2020 Aug 1;143(8):2332-2335. doi: 10.1093/brain/awaa226.

DOI:10.1093/brain/awaa226
PMID:32844192
Abstract
摘要

相似文献

1
Long duration response in Parkinson's disease: levodopa revisited.帕金森病的长期反应：左旋多巴再探讨
Brain. 2020 Aug 1;143(8):2332-2335. doi: 10.1093/brain/awaa226.
2
Levodopa treatment in Parkinson's disease: how does it affect dysphagia management?帕金森病的左旋多巴治疗：它如何影响吞咽困难的管理？
Parkinsonism Relat Disord. 2014 Mar;20(3):340-1. doi: 10.1016/j.parkreldis.2013.09.013. Epub 2013 Sep 20.
3
Levodopa, ayurveda and Parkinson's disease.左旋多巴、阿育吠陀与帕金森病。
J Neurol Sci. 2001 Feb 15;184(1):89-92. doi: 10.1016/s0022-510x(00)00499-8.
4
The neurochemistry of therapeutics: levodopa pharmacodynamics in Parkinson's disease.治疗学的神经化学：帕金森病中左旋多巴的药效学
Ann Neurol. 2001 Mar;49(3):285-7.
5
The variability of levodopa response in Parkinson's disease: is sensitization reversible?帕金森病中左旋多巴反应的变异性：敏化作用是否可逆？
Mov Disord. 2008 Apr 30;23(6):924; author reply 925. doi: 10.1002/mds.21893.
6
Levodopa: management of Parkinson's disease.左旋多巴：帕金森病的治疗
Mov Disord. 2002;17 Suppl 4:S23-37. doi: 10.1002/mds.5558.
7
Deprenyl and levodopa and Parkinson's disease progression.司来吉兰、左旋多巴与帕金森病进展
Ann Neurol. 1996 Aug;40(2):267-8. doi: 10.1002/ana.410400228.
8
Swallowing improvement after levodopa treatment in idiopathic Parkinson's disease: lack of evidence. Authors' reply.左旋多巴治疗特发性帕金森病后吞咽功能改善：缺乏证据。作者回复
Parkinsonism Relat Disord. 2014 Mar;20(3):342. doi: 10.1016/j.parkreldis.2013.10.028. Epub 2013 Nov 18.
9
Prosodic expression and levodopa in Parkinson's disease.帕金森病中的韵律表达与左旋多巴
Arq Neuropsiquiatr. 2013 Nov;71(11):831-2. doi: 10.1590/0004-282X20130199.
10
Levodopa and the progression of Parkinson's disease.左旋多巴与帕金森病的进展
N Engl J Med. 2005 Mar 31;352(13):1386; author reply 1386. doi: 10.1056/NEJM200503313521324.

引用本文的文献

1
Modulatory effect of levodopa on the basal ganglia-cerebellum connectivity in Parkinson's disease.左旋多巴对帕金森病基底神经节 - 小脑连接性的调节作用。
NPJ Parkinsons Dis. 2025 May 6;11(1):115. doi: 10.1038/s41531-025-00954-9.
2
Dopaminergic responsiveness and dopaminergic challenge tests of Parkinson's disease: a systematic review and meta-analysis.帕金森病的多巴胺能反应性及多巴胺能激发试验：一项系统评价与荟萃分析
J Neurol. 2025 Feb 1;272(2):176. doi: 10.1007/s00415-025-12894-8.
3
Quantified Striatal Dopaminergic Denervation as Predictor for Motor Outcomes in Parkinson's Disease.
定量纹状体多巴胺能去神经支配作为帕金森病运动结局的预测指标
Mov Disord Clin Pract. 2023 Apr 5;10(6):896-902. doi: 10.1002/mdc3.13726. eCollection 2023 Jun.
4
Inhaled levodopa for threatening impending OFF episodes in managing Parkinson's disease.吸入左旋多巴治疗帕金森病中即将出现的关期发作。
J Neural Transm (Vienna). 2023 Jun;130(6):821-826. doi: 10.1007/s00702-023-02636-3. Epub 2023 Apr 23.
5
Should "on-demand" treatments for Parkinson's disease OFF episodes be used earlier?帕金森病“关”期的“按需”治疗是否应更早使用？
Clin Park Relat Disord. 2022 Aug 12;7:100161. doi: 10.1016/j.prdoa.2022.100161. eCollection 2022.
6
Evaluation of the PREDIGT score's performance in identifying newly diagnosed Parkinson's patients without motor examination.在不进行运动检查的情况下评估PREDIGT评分在识别新诊断帕金森病患者方面的表现。
NPJ Parkinsons Dis. 2022 Jul 29;8(1):94. doi: 10.1038/s41531-022-00360-5.
7
Comparative efficacy of surgical approaches to disease modification in Parkinson disease.帕金森病疾病修饰手术方法的比较疗效
NPJ Parkinsons Dis. 2022 Mar 25;8(1):33. doi: 10.1038/s41531-022-00296-w.
8
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.一项评估普拉西奈单抗治疗早期帕金森病安全性和有效性的II期研究（帕萨迪纳研究）：原理、设计和基线数据
Front Neurol. 2021 Oct 1;12:705407. doi: 10.3389/fneur.2021.705407. eCollection 2021.